Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of CM336 injection in relapsed or refractory multiple myeloma
CTR20220308Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Sep 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in multiple myeloma (MM), sponsored by Keymed Biosciences. Started Sep 2022; status: active.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20220308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220308.